Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.49 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725039 | 0.93 | MAPT (0.57) | SMN1; SMN2RAB9ANPC1TP53ALOX15 | |
| SCHEMBL18502050 | 0.77 | MAPT (0.61) | SMN1; SMN2RAB9ANPC1TP53ALOX15 | |
| SCHEMBL1420533 | 0.75 | TRPV4 (0.57) | SMN1; SMN2RAB9ANPC1TP53ALOX15 | |
| SCHEMBL724095 | 0.74 | L3MBTL3 (0.49) | L3MBTL1L3MBTL3MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL4237552 | 0.73 | L3MBTL3 (0.71) | L3MBTL1L3MBTL3MBTD1TP53BP1L3MBTL4 | |
| Trifluoroacetic Acid SCHEMBL6986818 | 0.73 | CHKA (0.63) | SLC2A1SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL14528874 | 0.72 | L3MBTL3 (0.66) | SMN1; SMN2RAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL1420117 | 0.72 | LMNA (0.49) | SMN1; SMN2RAB9ANPC1TP53HTT | |
| Hydrochloric Acid SCHEMBL722840 | 0.72 | L3MBTL3 (0.69) | ALOX15L3MBTL1L3MBTL3MBTD1TP53BP1 | |
| SCHEMBL846069 | 0.72 | TRPV1 (0.61) | SMN1; SMN2RAB9ANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | claimed |
| CN-1902177-A | Novel piperidine derivative | BANYU PHARMA CO LTD (JP) | 2007-01-24 | — | — | CN | claimed |
| EP-1669350-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | claimed |
| EP-1669350-B1 | PIPERIDINE DERIVATIVES | MSD KK (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7834182-B2 | histamine H3 receptor antagonists; metabolic disorders, sleep disorders, cardiovascular disorders, alcoholism, drug addiction, memory disorders, Alzheimer's, Parkinson's disease; 2-(4-piperidinylpiperidinyl)pyrimidine compounds such as 2-[(4-piperidin-1-yl)piperidin-1-yl]-5-(3-pyridyl)pyrimidine | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090203710-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7547693-B2 | Such as N-methyl-N-(1-methylpiperidin-4-yl)-4-[4-(piperidin-1-yl)piperidin-1-yl]benzamide; histamine h3-antagonists | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
| CN-1902177-A | Novel piperidine derivative | BANYU PHARMA CO LTD (JP) | 2007-01-24 | — | — | CN | disclosed |
| EP-1669350-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105901-A1 | Novel piperidine derivative | HRH3, OPRM1, OPRK1 | SLC2A1 663/4885SMN1; SMN2 226/4885RAB9A 921/4885 |
| US-20090203710-A1 | Novel piperidine derivative | HRH3, OPRM1, HRH4 | SLC2A1 606/4885SMN1; SMN2 225/4885RAB9A 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.